SEC Form 4 · accession 0001144204-15-032023

ENDOCYTE INC · ECYT

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Fred A Middleton

Director

Period of report

May 14, 2015

Accepted (ET)

May 18, 2015 · 4:34 pm EDT

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0001235007

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I	Nature of ownership
Common Stock^F1,F2	May 14, 2015	A	2,250	$0.00	A	170,999	D
Common Stock^F3,F4	holding	—	—		—	1,017,304	I	By Sanderling Venture Partners V, L.P.
Common Stock^F3,F4	holding	—	—		—	831,461	I	By Sanderling Venture Partners VI Co-Investment Fund, L.P.
Common Stock^F3,F5	holding	—	—		—	267,491	I	By Sanderling Venture Partners V Co-Investment Fund, L.P.
Common Stock^F3,F4	holding	—	—		—	249,148	I	By Sanderling V Biomedical, L.P.
Common Stock^F3,F4	holding	—	—		—	162,170	I	By Sanderling V Biomedical Co-Investment Fund, L.P.
Common Stock^F3,F4	holding	—	—		—	113,315	I	By Sanderling V Limited Partnership
Common Stock^F3,F4	holding	—	—		—	100,828	I	By Sanderling V Beteiligungs GmbH & Co. KG
Common Stock^F3,F4	holding	—	—		—	10,049	I	By Sanderling VI Limited Partnership
Common Stock^F3,F4	holding	—	—		—	8,434	I	By Sanderling VI Beteiligungs GmbH & Co. KG
Common Stock^F3,F4	holding	—	—		—	785,417	I	By Sanderling V Strategic Exit Fund, L.P.

Table II — derivative securities

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Stock Option (right to buy)^F6	$6.02	May 14, 2015	A	13,500	A	—	May 14, 2025	Common Stock	13,500	13,500	D

Explanation of responses

F1Represents restricted stock units that will vest 100% on the business day prior to the next annual stockholder meeting following the date of grant, and will be paid in the form of one share of common stock for each restricted stock unit.
F2Includes a distribution from Sanderling Ventures Management V of 65,118 shares and from Sanderling Ventures Management VI of 28,631 shares on December 11, 2012, to Fred Middleton.
F3Mr. Middleton disclaims beneficial ownership of the shares directly held by the entities affiliated with Sanderling except to the extent of his individual pecuniary interest therein.
F4Fred Middleton is a managing director of Middleton, McNeil & Mills Associates V, LLC which has the ultimate voting and investment power over shares held of record by Sanderling V Beteiligungs GmbH & Co. KG, Sanderling V Biomedical Co-Investment Fund, L.P., Sanderling V Biomedical, L.P., Sanderling V Limited Partnership, Sanderling Venture Partners V, L.P., Sanderling Venture Partners VI Co-Investment Fund, L.P., Sanderling VI Beteiligungs GmbH and Co. KG, Sanderling VI Limited Partnership and Sanderling V Strategic Exit Fund, L.P. and he may be deemed to have voting and investment power over shares held of record by Sanderling V Beteiligungs GmbH & Co. KG, Sanderling V Biomedical Co-Investment Fund, L.P., Sanderling V Biomedical, L.P., Sanderling V Limited Partnership, Sanderling Venture Partners V, L.P., Sanderling Venture Partners VI Co-Investment Fund, L.P., Sanderling VI Beteiligungs GmbH and Co. KG, Sanderling V Strategic Exit Fund, L.P. and Sanderling VI Limited Partnership.
F5Fred Middleton is a managing director of Middleton, McNeil & Mills Associate V, LLC which has the ultimate voting and investment power over shares held of record by Sanderling Venture Partners V Co-Investment Fund, L.P. and he may be deemed to have voting and investment power over shares of record by Sanderling Venture Partners V Co-Investment Fund, L.P.
F6100% of options vest on the business day prior to the next annual stockholder meeting following the date of grant.